Publications by authors named "R Pantophlet"
Article Synopsis
- * The discovery of PLpro inhibitors is challenging due to the protease's flexible active site, which complicates the identification of effective drug candidates through traditional docking methods.
- * Researchers used a virtual screening method and advanced docking techniques to find potential noncovalent PLpro inhibitors, with the compound VPC-300195 showing promising inhibitory activity against the virus, paving the way for further drug development.
Background: Longer-term humoral responses to 2-dose coronavirus disease 2019 (COVID-19) vaccines remain incompletely characterized in people living with human immunodeficiency virus (HIV) (PLWH), as do initial responses to a third dose.
Methods: We measured antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain, angiotensin-converting enzyme 2 (ACE2) displacement, and viral neutralization against wild-type and Omicron strains up to 6 months after 2-dose vaccination, and 1 month after the third dose, in 99 PLWH receiving suppressive antiretroviral therapy and 152 controls.
Results: Although humoral responses naturally decline after 2-dose vaccination, we found no evidence of lower antibody concentrations or faster rates of antibody decline in PLWH compared with controls after accounting for sociodemographic, health, and vaccine-related factors.
Background: Third coronavirus disease 2019 (COVID-19) vaccine doses are broadly recommended, but immunogenicity data remain limited, particularly in older adults.
Methods: We measured circulating antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain, ACE2 displacement, and virus neutralization against ancestral and omicron (BA.1) strains from prevaccine up to 1 month following the third dose, in 151 adults aged 24-98 years who received COVID-19 mRNA vaccines.
Article Synopsis
- Researchers investigated humoral responses to COVID-19 vaccines in people living with HIV (PLWH) compared to controls, focusing on antibody levels and viral neutralization over time.
- They found no significant differences in antibody concentrations or neutralization abilities between PLWH and controls after two doses, indicating that HIV does not negatively impact vaccine responses when on suppressive therapy.
- A third vaccine dose led to significantly enhanced antibody responses in PLWH, although responses against the Omicron variant were weaker relative to wild-type, highlighting the importance of booster doses for improved immunity.
Humoral responses to COVID-19 vaccines in people living with HIV (PLWH) remain incompletely characterized. We measured circulating antibodies against the SARS-CoV-2 spike protein receptor-binding domain (RBD), ACE2 displacement and viral neutralization activities one month following the first and second COVID-19 vaccine doses, and again 3 months following the second dose, in 100 adult PLWH and 152 controls. All PLWH were receiving suppressive antiretroviral therapy, with median CD4+ T-cell counts of 710 (IQR 525-935) cells/mm, though nadir CD4+ T-cell counts ranged as low as <10 cells/mm.
View Article and Find Full Text PDF